Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene ROS1
Variant G2032R
Impact List missense
Protein Effect unknown
Gene Variant Descriptions ROS1 G2032R lies within the protein kinase domain of the Ros1 protein (UniProt.org). G2032R has been associated with resistance to Ros1 tyrosine kinase inhibitors in the context of ROS1 fusions in patients (PMID: 23724914, PMID: 25033171, PMID: 29477381), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2022).
Associated Drug Resistance Y

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Transcript NM_002944.2
gDNA chr6:g.117317184C>T
cDNA c.6094G>A
Protein p.G2032R
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_002944.2 chr6:g.117317184C>T c.6094G>A p.G2032R RefSeq GRCh38/hg38
XM_011536051.2 chr6:g.117317187C>T c.6094G>A p.G2032R RefSeq GRCh38/hg38
NM_002944 chr6:g.117317184C>T c.6094G>A p.G2032R RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ROS1 G2032R Advanced Solid Tumor predicted - sensitive Lorlatinib Preclinical - Biochemical Actionable In a preclinical study, Lorbrena (lorlatinib) inhibited kinase activity of a transformed cell line expressing ROS1 G2032R in culture (PMID: 32918045). 32918045
ROS1 G2032R Advanced Solid Tumor predicted - sensitive SAF-189s Preclinical - Biochemical Actionable In a preclinical study, SAF-189s inhibited kinase activity of a transformed cell line expressing ROS1 G2032R in culture (PMID: 32918045). 32918045
ROS1 G2032R Advanced Solid Tumor predicted - resistant Crizotinib Preclinical - Biochemical Actionable In a preclinical study, Xalkori (crizotinib) treatment did not inhibit kinase activity of a transformed cell line expressing ROS1 G2032R in culture (PMID: 32918045). 32918045
ROS1 G2032R Advanced Solid Tumor predicted - resistant Ceritinib Preclinical - Biochemical Actionable In a preclinical study, Zykadia (ceritinib) treatment did not inhibit kinase activity of a transformed cell line expressing ROS1 G2032R in culture (PMID: 32918045). 32918045
ROS1 fusion ROS1 G2032R Advanced Solid Tumor predicted - sensitive Repotrectinib Phase I Actionable In a Phase I (TRIDENT-1) trial, Repotrectinib (TPX-0005) treatment resulted in partial response in a patient with advanced solid tumor harboring ROS1 G2032R in the context of ROS1 fusion (J Clin Oncol 36, 2018 (suppl; abstr 2513); NCT03093116). detail...
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Molecular Profile Protein Effect Treatment Approaches
ROS1 G2032R unknown
ROS1 fusion ROS1 G2032R